Ceryvyn Therapeutics (CKDXF) Net Income by Year
Ceryvyn Therapeutics Ltd reported a net loss of $162.8M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Ceryvyn Therapeutics Ltd has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
CKDXF Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
CKDXF Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Ceryvyn Therapeutics Ltd financials
Frequently Asked Questions
Ceryvyn Therapeutics Ltd reported a net loss of $162.8M in fiscal year 2025.
Ceryvyn Therapeutics Ltd (CKDXF) reported a $220.2M net loss in fiscal year 2024 and a $162.8M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Across the 7 fiscal years this page covers, Ceryvyn Therapeutics Ltd (CKDXF) net income went from -$15.0M in fiscal year 2019 to -$162.8M in fiscal year 2025.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Ceryvyn Therapeutics Ltd (CKDXF) reported on that line in every period on record.